RCUS
Arcus Biosciences, Inc.
Latest close $28.80 as of Aug 4, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 5 parsed filing(s) · 2 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Dec 31, 2025 observed Jan 8, 2026 filed · 8d Schedule 13G amendment | Reported accumulation | 12.7M +3.0M | 12.00% +1.40 pts | $23.83 | $21.35 | $28.80 |
| BlackRock CIK0002012383 | Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 9.7M | $28.80 | |||
| BlackRock CIK0002012383 | Sep 30, 2024 observed Nov 8, 2024 filed · 39d Schedule 13G amendment | Reported shares unchanged | 9.7M 0 | 10.60% 0.00 pts | $17.85 | $28.80 |